Philip Mease, MD, clinical professor, University of Washington School of Medicine, Seattle, discusses the treatment of psoriatic arthritis (PsA) by inhibiting interleukin (IL)-17A with the highly specific monoclonal antibody ixekizumab in the video below. Dr Mease and colleagues recently published results from a phase 3 randomized clinical trial investigating the safety and efficacy of ixekizumab in patients with active PsA in the Annals of the Rheumatic Diseases.1
They reported that the use of ixekizumab for 24 weeks resulted in reduced PsA disease activity, as measured by the 28-joint disease activity score using C-reactive protein (DAS28-CRP) in biologic-naive patients with active PsA.
Please scroll down to view the video.
- Mease PJ, van der Heijde DV, Ritchlin CT, et al; SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2016; doi:10.1136/annrheumdis-2016-209709 [Epub ahead of print]